APOBEC3 upregulation drives gemcitabine resistance

IF 23.5 1区医学 Q1 ONCOLOGY

Nature cancer Pub Date : 2024-05-22 DOI:10.1038/s43018-024-00755-8

John Maciejowski, Taha Mohamed

引用次数: 0

Abstract

Gemcitabine is a widely used chemotherapy drug that acts by targeting DNA replication. Understanding why many tumors are unresponsive to gemcitabine is a clinical challenge. A new study in Nature Cancer reports that upregulation of the cytidine deaminases APOBEC3C and APOBEC3D facilitates resistance to gemcitabine by protecting cells against DNA replication stress.

Abstract Image

查看原文本刊更多论文

APOBEC3上调驱动吉西他滨耐药

吉西他滨是一种广泛使用的化疗药物，通过靶向 DNA 复制发挥作用。了解许多肿瘤对吉西他滨无反应的原因是一项临床挑战。自然-癌症》（Nature Cancer）杂志上的一项新研究报告说，胞苷脱氨酶APOBEC3C和APOBEC3D的上调可保护细胞免受DNA复制压力的影响，从而促进对吉西他滨的耐药性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature cancer Medicine-Oncology

CiteScore

31.10

自引率

1.80%

发文量

129

期刊介绍： Cancer is a devastating disease responsible for millions of deaths worldwide. However, many of these deaths could be prevented with improved prevention and treatment strategies. To achieve this, it is crucial to focus on accurate diagnosis, effective treatment methods, and understanding the socioeconomic factors that influence cancer rates. Nature Cancer aims to serve as a unique platform for sharing the latest advancements in cancer research across various scientific fields, encompassing life sciences, physical sciences, applied sciences, and social sciences. The journal is particularly interested in fundamental research that enhances our understanding of tumor development and progression, as well as research that translates this knowledge into clinical applications through innovative diagnostic and therapeutic approaches. Additionally, Nature Cancer welcomes clinical studies that inform cancer diagnosis, treatment, and prevention, along with contributions exploring the societal impact of cancer on a global scale. In addition to publishing original research, Nature Cancer will feature Comments, Reviews, News & Views, Features, and Correspondence that hold significant value for the diverse field of cancer research.